CA3145082C - Procedes de traitement du trouble de stress post traumatique - Google Patents

Procedes de traitement du trouble de stress post traumatique Download PDF

Info

Publication number
CA3145082C
CA3145082C CA3145082A CA3145082A CA3145082C CA 3145082 C CA3145082 C CA 3145082C CA 3145082 A CA3145082 A CA 3145082A CA 3145082 A CA3145082 A CA 3145082A CA 3145082 C CA3145082 C CA 3145082C
Authority
CA
Canada
Prior art keywords
nutritional supplement
mmol
arginine
lysine
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3145082A
Other languages
English (en)
Other versions
CA3145082A1 (fr
Inventor
Amy L. Heaton
Mitchell K. Friedlander
Dennis W. Gay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quality IP Holdings LLC
Original Assignee
Quality IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/623,101 external-priority patent/US9198889B2/en
Priority claimed from US13/623,097 external-priority patent/US8808763B2/en
Application filed by Quality IP Holdings LLC filed Critical Quality IP Holdings LLC
Publication of CA3145082A1 publication Critical patent/CA3145082A1/fr
Application granted granted Critical
Publication of CA3145082C publication Critical patent/CA3145082C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Il est décrit un supplément nutritif et son utilisation par voie orale pour le traitement du stress post-traumatique chez une personne. Le supplément nutritionnel peut comprendre, par exemple, de la L-arginine, de loxoproline, de la L-lysine, du N-acétyle L-cystéine, et de la L-glutamine.
CA3145082A 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique Active CA3145082C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/623,101 US9198889B2 (en) 2012-09-19 2012-09-19 Methods for treating post-traumatic stress disorder
US13/623,097 US8808763B2 (en) 2012-09-19 2012-09-19 Methods for improving sleep efficiency in healthy human beings
US13/623,101 2012-09-19
US13/623,097 2012-09-19
CA2885570A CA2885570C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2885570A Division CA2885570C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Publications (2)

Publication Number Publication Date
CA3145082A1 CA3145082A1 (fr) 2014-03-27
CA3145082C true CA3145082C (fr) 2024-02-13

Family

ID=50341940

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3145082A Active CA3145082C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique
CA2885570A Active CA2885570C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2885570A Active CA2885570C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Country Status (2)

Country Link
CA (2) CA3145082C (fr)
WO (1) WO2014047323A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions

Also Published As

Publication number Publication date
WO2014047323A1 (fr) 2014-03-27
CA3145082A1 (fr) 2014-03-27
CA2885570A1 (fr) 2014-03-27
CA2885570C (fr) 2022-03-15

Similar Documents

Publication Publication Date Title
US9198889B2 (en) Methods for treating post-traumatic stress disorder
US8808763B2 (en) Methods for improving sleep efficiency in healthy human beings
US10369182B2 (en) Compositions and methods for treating insomnia and other sleep related disorders
CZ295248B6 (cs) Farmaceutický prostředek k léčení syndromu chronické únavy či syndromu fibromyalgie
MX2014010939A (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
US6498247B2 (en) Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions
Sydenstricker et al. The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders
JP2024069498A (ja) エルゴチオネイン又はその塩を含有する睡眠改善用組成物
US20130017278A1 (en) Composition and method for improving brain function
WO2018022848A1 (fr) A2-73 en tant qu'agent thérapeutique contre l'insomnie, l'anxiété et l'agitation
CA3145082C (fr) Procedes de traitement du trouble de stress post traumatique
JP2014065695A (ja) ロイシンを含有する睡眠改善剤
US10583095B2 (en) Method for stress management and overall health status improvement and compositions used therein
BR112020007657A2 (pt) leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento da síndrome das pernas inquietas (rls)
Dighikar et al. A Rare Case of Wilson’s Disease in a 17 Years Old Girl
JP2022003023A (ja) アレルギー性鼻炎症状改善用組成物、アレルギー性鼻炎症状に起因するｑｏｌ低下改善用組成物、及び、アレルギー性鼻炎症状に起因するくしゃみ抑制用組成物
JP2014065694A (ja) アスパラギン酸を含有する睡眠改善剤
CN110384690A (zh) 异甘草素在制备抗焦虑药物中的应用
US20190254992A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
JP7185260B2 (ja) 悪夢障害の治療用医薬組成物
US20240197704A1 (en) Treatment methods and compositions comprising perampanel
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
US11219659B2 (en) Methods and compositions for treating schizophrenia and schizoaffective disorders
WO2020040216A1 (fr) Agent de réduction de température de corps de noyau, produit alimentaire et aide au sommeil
RU2545709C1 (ru) Способ коррекции психических расстройств у больных с глиальными опухолями головного мозга различной локализации в раннем послеоперационном периоде

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105

EEER Examination request

Effective date: 20220105